Suppr超能文献

探索NAA40在肝细胞癌免疫浸润及预后预测中的作用。

Exploring the role of NAA40 in immune infiltrates and prognostic prediction in hepatocellular carcinoma.

作者信息

Zhou Tong, Cao Jun, Tang Qingqin, Jin Jieyu, Liang Yuting, Feng Bin

机构信息

Center for Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.

Medical College of Soochow University Suzhou, Jiangsu, China.

出版信息

Am J Clin Exp Immunol. 2024 Feb 25;13(1):26-34. doi: 10.62347/UGPH7404. eCollection 2024.

Abstract

NAA40 belongs to the N-terminal acetyltransferase (NATs) family, responsible for protein N-terminal modification, and it exerts crucial roles across various cancers. However, its impact on patient prognosis and immune infiltration in hepatocellular carcinoma (HCC) remains elusive. To address this, our study delved into the comprehensive analysis of NAA40 in the context of cancer. Our pan-cancer analysis unveiled elevated NAA40 expression in multiple tumor types, including BLCA, BRCA, CHOL, COAD, ESCA, HNSC, LIHC, LUAD, LUSC, STAD, and THCA. Additionally, through a comprehensive examination across various cancer types within TCGA, we discovered that high NAA40 gene expression correlated with poor prognosis in HCC, pointing toward its role in promoting oncogenesis. Further investigation illuminated the association of increased NAA40 expression with T stage, pathologic stage, tumor status, and histologic grade. Interestingly, we noted a significant inverse correlation between NAA40 expression and the infiltration levels of immune cells, such as DC cells, neutrophils, NK cells, and T cells, in liver cancer. This observation underpins the hypothesis that NAA40 influences HCC development by modulating immune cell infiltration. Functional enrichment analysis provided valuable insights into the pathways influenced by NAA40. Enriched pathways encompassed oxidative phosphorylation, xenobiotic metabolism, bile acid metabolism, fatty acid metabolism, G2M checkpoint, and E2F targets. These findings collectively position NAA40 as a potential biomarker for prognostic prediction and monitoring the effects of immunotherapy in HCC.

摘要

NAA40属于N端乙酰转移酶(NATs)家族,负责蛋白质N端修饰,并且在各种癌症中发挥关键作用。然而,其对肝细胞癌(HCC)患者预后和免疫浸润的影响仍不清楚。为了解决这个问题,我们的研究深入探讨了癌症背景下NAA40的综合分析。我们的泛癌分析揭示了NAA40在多种肿瘤类型中表达升高,包括膀胱癌(BLCA)、乳腺癌(BRCA)、胆管癌(CHOL)、结肠癌(COAD)、食管癌(ESCA)、头颈部鳞状细胞癌(HNSC)、肝癌(LIHC)、肺腺癌(LUAD)、肺鳞癌(LUSC)、胃癌(STAD)和甲状腺癌(THCA)。此外,通过对TCGA中各种癌症类型的全面检查,我们发现NAA40基因高表达与HCC患者预后不良相关,表明其在促进肿瘤发生中的作用。进一步研究阐明了NAA40表达增加与T分期、病理分期、肿瘤状态和组织学分级之间的关联。有趣的是,我们注意到肝癌中NAA40表达与免疫细胞如树突状细胞(DC细胞)、中性粒细胞、自然杀伤细胞(NK细胞)和T细胞的浸润水平呈显著负相关。这一观察结果支持了NAA40通过调节免疫细胞浸润影响HCC发展的假说。功能富集分析为受NAA40影响的通路提供了有价值的见解。富集的通路包括氧化磷酸化、异源物质代谢、胆汁酸代谢、脂肪酸代谢、G2M检查点和E2F靶点。这些发现共同将NAA40定位为HCC预后预测和监测免疫治疗效果的潜在生物标志物。

相似文献

1
Exploring the role of NAA40 in immune infiltrates and prognostic prediction in hepatocellular carcinoma.
Am J Clin Exp Immunol. 2024 Feb 25;13(1):26-34. doi: 10.62347/UGPH7404. eCollection 2024.
3
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Comput Struct Biotechnol J. 2022 Jun 18;20:3106-3119. doi: 10.1016/j.csbj.2022.06.039. eCollection 2022.
4
CCND1 as a Prognostic and Diagnostic Biomarker and the Impact of Its Epigenetic Alterations on Cancer Survival.
Cureus. 2024 Jul 27;16(7):e65504. doi: 10.7759/cureus.65504. eCollection 2024 Jul.
5
Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes.
Front Oncol. 2021 Jun 2;11:691950. doi: 10.3389/fonc.2021.691950. eCollection 2021.
6
Pan-Cancer Analysis Revealed as a New Biomarker for Prognosis and Immunotherapy.
J Oncol. 2022 Jan 12;2022:3477148. doi: 10.1155/2022/3477148. eCollection 2022.
7
Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
Comput Struct Biotechnol J. 2022 Sep 17;20:5226-5234. doi: 10.1016/j.csbj.2022.09.021. eCollection 2022.
8
Identifies microtubule-binding protein as a novel cancer biomarker associated with ferroptosis and tumor microenvironment.
Comput Struct Biotechnol J. 2022 Jun 24;20:3322-3335. doi: 10.1016/j.csbj.2022.06.046. eCollection 2022.
10
Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer.
Cells. 2022 Apr 22;11(9):1427. doi: 10.3390/cells11091427.

引用本文的文献

本文引用的文献

1
Cancer statistics, 2023.
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
2
Hepatocellular Carcinoma: New Developments.
Clin Liver Dis. 2023 Feb;27(1):85-102. doi: 10.1016/j.cld.2022.08.004. Epub 2022 Oct 18.
3
Hepatocellular Carcinoma.
Crit Care Nurs Clin North Am. 2022 Sep;34(3):289-301. doi: 10.1016/j.cnc.2022.04.004. Epub 2022 Jul 20.
4
Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome.
Oxid Med Cell Longev. 2021 Dec 31;2021:5175581. doi: 10.1155/2021/5175581. eCollection 2021.
5
Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes.
Front Oncol. 2021 Jun 2;11:691950. doi: 10.3389/fonc.2021.691950. eCollection 2021.
6
Novel Bisubstrate Inhibitors for Protein N-Terminal Acetyltransferase D.
J Med Chem. 2021 Jun 24;64(12):8263-8271. doi: 10.1021/acs.jmedchem.1c00141. Epub 2021 Jun 10.
7
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Int J Mol Sci. 2021 May 28;22(11):5801. doi: 10.3390/ijms22115801.
9
N-Terminal Acetyltransferases Are Cancer-Essential Genes Prevalently Upregulated in Tumours.
Cancers (Basel). 2020 Sep 15;12(9):2631. doi: 10.3390/cancers12092631.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验